Eric Easom - AN2 Therapeutics CEO, Cofounder
| ANTX Stock | USD 1.46 0.05 3.55% |
Insider
Eric Easom is CEO, Cofounder of AN2 Therapeutics
| Age | 57 |
| Address | 1800 El Camino Real, Menlo Park, CA, United States, 94027 |
| Phone | 650 331 9090 |
| Web | https://www.an2therapeutics.com |
Eric Easom Latest Insider Activity
Tracking and analyzing the buying and selling activities of Eric Easom against AN2 Therapeutics stock is an integral part of due diligence when investing in AN2 Therapeutics. Eric Easom insider activity provides valuable insight into whether AN2 Therapeutics is net buyers or sellers over its current business cycle. Note, AN2 Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell AN2 Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Eric Easom over a year ago Purchase by Eric Easom of 10000 shares of AN2 Therapeutics | ||
Eric Easom over a year ago Acquisition by Eric Easom of 267650 shares of AN2 Therapeutics subject to Rule 16b-3 |
AN2 Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3219) % which means that it has lost $0.3219 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5356) %, meaning that it created substantial loss on money invested by shareholders. AN2 Therapeutics' management efficiency ratios could be used to measure how well AN2 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.44 in 2025. Return On Capital Employed is likely to drop to -0.53 in 2025. At this time, AN2 Therapeutics' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 115.2 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 915.7 K in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Wim Souverijns | Pharvaris BV | 54 | |
| , MBA | Molecular Partners AG | 51 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Peng MD | Pharvaris BV | 47 | |
| Thomas Shenk | Pmv Pharmaceuticals | 77 | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
| Arnold Levine | Pmv Pharmaceuticals | 85 | |
| Michael Gait | PepGen | N/A | |
| Hunter MD | Aerovate Therapeutics | 59 | |
| Crystal Mercado | Acrivon Therapeutics, Common | N/A | |
| Peter MD | Acrivon Therapeutics, Common | 62 | |
| Erick MD | Acrivon Therapeutics, Common | 67 | |
| Jc MD | Adagene | 60 | |
| CPA MBA | Pharvaris BV | 63 | |
| Brian MD | Rezolute | 50 | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 66 | |
| James McArthur | PepGen | 63 | |
| Alexander Zurcher | Molecular Partners AG | 50 | |
| Eric Devroe | Acrivon Therapeutics, Common | 46 | |
| Jennifer Cormier | PepGen | N/A | |
Management Performance
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.32 |
AN2 Therapeutics Leadership Team
Elected by the shareholders, the AN2 Therapeutics' board of directors comprises two types of representatives: AN2 Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AN2. The board's role is to monitor AN2 Therapeutics' management team and ensure that shareholders' interests are well served. AN2 Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AN2 Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA BS, Chief Officer | ||
| Vince Hernandez, Senior Chemistry | ||
| Eric Easom, CEO, Cofounder | ||
| Michael Alley, CoFounder Biology | ||
| Lucy CPA, Principal CFO | ||
| Stephen Prior, Chief Officer | ||
| Paul MD, Chief Officer | ||
| Sanjay Chanda, Chief Officer | ||
| Josh Eizen, Chief Sec | ||
| Jennifer Huber, Senior Quality | ||
| Joshua JD, Chief Secretary | ||
| MD FACP, CoFounder Advisor | ||
| Joseph Zakrzewski, Cofounder Chairman |
AN2 Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AN2 Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.32 | ||||
| Current Valuation | (53.12 M) | ||||
| Shares Outstanding | 29.88 M | ||||
| Shares Owned By Insiders | 22.50 % | ||||
| Shares Owned By Institutions | 46.30 % | ||||
| Number Of Shares Shorted | 78.58 K | ||||
| Price To Earning | 3.96 X | ||||
| Price To Book | 0.48 X | ||||
| EBITDA | 4.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.